| Functional aspects of T cell diversity in visceral leishmaniasis JJ Jawed, S Dutta, S Majumdar Biomedicine & Pharmacotherapy 117, 109098, 2019 | 34 | 2019 |
| TBX2 drives neuroendocrine prostate cancer through exosome-mediated repression of miR-200c-3p GK Patel, S Dutta, M Mahmud Syed, S Ramachandran, M Sharma, ... Cancers 13 (19), 5020, 2021 | 9 | 2021 |
| TBX2 driven switch from Androgen Receptor to Glucocorticoid Receptor signaling confers therapeutic resistance in Prostate Cancer S Dutta, GK Patel, H Khedmatgozar, D Latour, M Tripathi, S Nandana bioRxiv, 2023.05. 07.539754, 2023 | 1 | 2023 |
| A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers enzalutamide resistance in prostate cancer S Dutta, GK Patel, H Khedmatgozar, D Latour, J Welsh, M Tripathi, ... Cancer Research 84 (6_Supplement), 6603-6603, 2024 | | 2024 |
| TIAM1 signaling drives prostatic budding and branching phenotypes and is a potential therapeutic target for BPH H Khedmatgozar, S Dutta, M Dominguez, D Latour, M Johnson, M Fokar, ... bioRxiv, 2024.02. 02.578055, 2024 | | 2024 |
| Abstract A011: TBX2 acts as a molecular switch to downregulate androgen receptor and upregulate glucocorticoid receptor signaling in castrate resistant prostate cancer S Dutta, G Patel, H Khedmatgozar, D Latour, M Tripathi, S Nandana Cancer Research 83 (11_Supplement), A011-A011, 2023 | | 2023 |
| TBX2 acts as a molecular switch to downregulate androgen receptor and upregulate glucocorticoid receptor signaling in castrate resistant prostate cancer S Dutta, G Patel, H Khedmatgozar, D Latour, M Tripathi, S Nandana Cancer Research 83 (7_Supplement), 1445-1445, 2023 | | 2023 |
| Abstract B024: TBX2highmiR-375-3plowRBPJhigh signaling drives prostate cancer bone metastatic phenotype via exosomes GK Patel, S Dutta, H Khedmatgozar, M Tripathi, S Nandana Cancer Research 83 (2_Supplement_2), B024-B024, 2023 | | 2023 |
| TBX2 promotes prostate cancer bone-metastatic phenotype through exosomal microRNA-375-3p GK Patel, S Dutta, H Khedmatgozar, M Tripathi, S Nandana Cancer Research 82 (12_Supplement), 5999-5999, 2022 | | 2022 |
